Saw Palmetto (Serenoa repens) is a bit different thing. SP is supposed to contain an inhibitor of 5-alpha-reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT), which might cause scalp temporal recession and pattern hair loss, excessive facial, axillary, pubic, and body hair growth, and prostate hyperplasia and prostate cancer risk. In adults, that is, because during the puberty it's responsible for, for example, development of male genitalia.
Some researches show, that SP might be efficient, so, apparently, results are individual. Finasteride, which is 18,000 times more potent, than Saw palmetto, is proved effective against alopecia 1mg) and benign prostate hyperplasia - BPH (5mg). In most EU countries, you need a doctor prescription to get finasteride, so, Saw palmetto can be an interesting alternative (or wasted money 😆).
And some other researches claim, that saw palmetto is no more effective, than placebo.
My goals are:
- stimulate scalp hair growth
- reduce body hair
- do something good for the prostate
It might take 4-6 months, though, to get to any conclusions...
https://pubmed.ncbi.nlm.nih.gov/33313047/
Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia
Abstract
Saw palmetto (SP), a botanical extract with antiandrogenic properties, has gained commercial popularity for its purported benefits on hair regrowth. To summarize published evidence on the efficacy, safety, and tolerability of supplements containing SP in the treatment of alopecia, we conducted a PubMed, Google Scholar, and Cochrane database search using the following terms: (saw palmetto and hair loss), (saw palmetto and androgenetic alopecia), and (saw palmetto and natural supplement and alopecia). Five randomized clinical trials (RCTs) and 2 prospective cohort studies demonstrated positive effects of topical and oral supplements containing SP (100-320 mg) among patients with androgenetic alopecia (AGA) and telogen effluvium. Sixty percent improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized disease progression among 52% were noted with use of various topical and oral SP-containing supplements. SP was well tolerated and not associated with serious adverse events in alopecia patients. Although robust high-quality data are lacking, supplements containing SP may be a treatment option for patients with AGA, telogen effluvium, and self-perceived hair thinning. Further large-scale RCTs focusing on the sole contribution of SP to hair growth outcomes are needed to confirm efficacy and determine long-term adverse events.